United Laboratories International Holdings (FRA:UNJ) 3-Year EBITDA Growth Rate : 9.90% (As of Jun. 2023)

View and export this data going back to 2007. Start your Free Trial

What is United Laboratories International Holdings 3-Year EBITDA Growth Rate?

United Laboratories International Holdings's EBITDA per Share for the six months ended in Jun. 2023 was €0.14.

During the past 12 months, United Laboratories International Holdings's average EBITDA Per Share Growth Rate was 63.40% per year. During the past 3 years, the average EBITDA Per Share Growth Rate was 9.90% per year. During the past 5 years, the average EBITDA Per Share Growth Rate was 11.20% per year. During the past 10 years, the average EBITDA Per Share Growth Rate was 6.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of United Laboratories International Holdings was 29.60% per year. The lowest was -18.30% per year. And the median was 8.90% per year.

Competitive Comparison of United Laboratories International Holdings's 3-Year EBITDA Growth Rate

For the Drug Manufacturers - Specialty & Generic subindustry, United Laboratories International Holdings's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

United Laboratories International Holdings's 3-Year EBITDA Growth Rate Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, United Laboratories International Holdings's 3-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where United Laboratories International Holdings's 3-Year EBITDA Growth Rate falls into.

United Laboratories International Holdings 3-Year EBITDA Growth Rate Calculation

This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

United Laboratories International Holdings (FRA:UNJ) 3-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

United Laboratories International Holdings 3-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of United Laboratories International Holdings's 3-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

United Laboratories International Holdings (FRA:UNJ) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » United Laboratories International Holdings Ltd (FRA:UNJ) » Definitions » 3-Year EBITDA Growth Rate

Comparable Companies

Traded in Other Exchanges

ULIHF:USA 03933:Hong Kong UNJ:Germany

Address

No. 6 Fuk Wang Street, Yuen Long Industrial Estate, New Territories, Hong Kong, HKG

Website

http://www.tul.com.cn

United Laboratories International Holdings Ltd is a major drug manufacturing company. United Laboratories is organized into three revenue streams, including Intermediate products, Bulk medicine, and Finished products. The company's Finished products segment includes antibiotic products, insulin series products, and other medicines. The vast majority of the company's revenue is derived from its Bulk medicine segment, followed by Finished products. Most of the company's sales are generated in China, followed by Europe and India.

United Laboratories International Holdings (FRA:UNJ) Headlines

No Headlines